@article {Nishiura2020.02.28.20029272, author = {Hiroshi Nishiura and Hitoshi Oshitani and Tetsuro Kobayashi and Tomoya Saito and Tomimasa Sunagawa and Tamano Matsui and Takaji Wakita and MHLW COVID-19 Response Team and Motoi Suzuki}, title = {Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19)}, elocation-id = {2020.02.28.20029272}, year = {2020}, doi = {10.1101/2020.02.28.20029272}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective To identify common features of cases with novel coronavirus disease (COVID-19) so as to better understand what factors promote secondary transmission including superspreading events.Methods A total of 110 cases were examined among eleven clusters and sporadic cases, and investigated who acquired infection from whom. The clusters included four in Tokyo and one each in Aichi, Fukuoka, Hokkaido, Ishikawa, Kanagawa and Wakayama prefectures. The number of secondary cases generated by each primary case was calculated using contact tracing data.Results Of the 110 cases examined, 27 (24.6\%) were primary cases who generated secondary cases. The odds that a primary case transmitted COVID-19 in a closed environment was 18.7 times greater compared to an open-air environment (95\% confidence interval [CI]: 6.0, 57.9).Conclusions It is plausible that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events. Our findings are also consistent with the declining incidence of COVID-19 cases in China, as gathering in closed environments was prohibited in the wake of the rapid spread of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers, H.N.: 17H04701, 17H05808, 18H04895 and 19H01074], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized dataset will be provided by the corresponding author upon request.}, URL = {https://www.medrxiv.org/content/early/2020/04/16/2020.02.28.20029272}, eprint = {https://www.medrxiv.org/content/early/2020/04/16/2020.02.28.20029272.full.pdf}, journal = {medRxiv} }